🇺🇸

Distress Insolvency

US SEC Filing Intelligence · 156 digests

· daily

US Corporate Distress Financial Stress SEC Filings — September 02, 2026

The six filings paint a stark picture of corporate distress concentrated in the small-cap and micro-cap space, with three companies facing imminent Nasdaq delisting (Triller, IRIDEX, Reborn Coffee) and one (TScan Therapeutics) executing a drastic restructuring to avoid a cash crunch. A common theme is severe capital constraints forcing strategic pivots or asset sales, as seen in TScan's 75% workforce reduction and Twinlab's assignment for the benefit of creditors. Period-over-period data is limited in these event-driven filings, but the aggregate signals point to a sector-wide liquidity crisis among undercapitalized life sciences and consumer companies. The most actionable intelligence lies in the divergence between companies with viable turnaround plans (TScan, cbdMD/Twinlab) and those with unresolved compliance issues (Triller, Reborn Coffee). Insider activity is notably absent across all filings, suggesting management teams are either constrained or lacking conviction. The forward-looking catalyst calendar is dominated by Nasdaq compliance deadlines and IND filings, creating a binary event-driven trading environment.

6 high priority 6 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 02, 2026

The sole filing in this session involves Twinlab Consolidated Holdings, Inc., which is undergoing an Assignment for the Benefit of Creditors (ABC) proceeding—a common alternative to Chapter 11 bankruptcy. cbdMD, Inc. has entered a definitive asset purchase agreement to acquire Twinlab's operating assets and brands, including Twinlab, Reserveage, Metabolife, and Alvita Tea. The transaction is expected to boost cbdMD's trailing twelve-month revenue to approximately $30 million, a 40% increase over its standalone revenue, though this figure is illustrative and not guaranteed. The deal is subject to court approval, reflecting the insolvency-driven nature of the sale. No period-over-period comparisons, insider activity, or forward-looking guidance were provided in the filing, limiting trend analysis. The mixed sentiment stems from the strategic opportunity for cbdMD versus the underlying distress of Twinlab. This is a quiet session with no other bankruptcy or insolvency filings, making this the sole actionable event.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 01, 2026

The digest reveals a sharp and concentrated wave of distress across eight US-listed companies, centred overwhelmingly on Nasdaq listing deficiencies and acute solvency risks. The dominant theme is a cascade of late-filing violations, with four separate companies (XTI Aerospace, Borealis Foods, CID Holdco, Heritage Distilling) receiving delinquency notices for missing their Q2 2026 10-Q deadlines, pointing to systemic accounting or disclosure issues. The most severe event is BioXcel Therapeutics entering Chapter 11 bankruptcy, a binary outcome that underscores the ultimate crystallization of distress. Insider activity is notably absent across all filings, weakening management's credibility as a signalling tool. Period-over-period comparisons were sparse in these event-driven disclosures, but the sheer density of going-concern warnings (XTI Aerospace) and compound listing failures (authID, CID Holdco) signals that a subset of micro-cap names is facing a liquidity and governance crunch. The critical market implication is that the delisting risk is not isolated; each new deficiency creates a compounding risk that can accelerate the timeline to bankruptcy or forced M&A, as seen in BioXcel's case.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 31, 2026

This digest captures a surge in corporate distress signals among US-listed companies, with three of four filings involving Nasdaq/NYSE delisting threats or actions on a single day (August 26, 2026). The cluster spans micro-cap and small-cap firms in industrials (Northann Corp.), telecom equipment (Cambium Networks), and battery technology (Microvast Holdings), suggesting a broad-based liquidity and compliance crisis rather than a sector-specific issue. Period-over-period data from the enriched filings reveals a pattern of deteriorating financial health: all three distressed companies show negative revenue growth trends (avg -12% YoY) and margin compression (avg -180 bps YoY), with no insider buying to signal management confidence. The fourth filing (Profusa, Inc.) narrowly avoided delisting after a reverse split, but its mixed sentiment and low materiality (6/10) indicate ongoing fragility. Critically, no forward-looking guidance or capital allocation actions (dividends, buybacks) were reported across any filing, underscoring a complete lack of positive catalysts. The most actionable insight is the timing cluster—three delisting events within one week—which may signal a broader regulatory crackdown or market liquidity event that investors should monitor for contagion risk.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 28, 2026

The USA Corporate Distress & Bankruptcy stream for August 28, 2026, reveals a severe wave of Nasdaq and NYSE American non-compliance events, with 14 filings concentrated on going concern warnings, delisting notices, and bankruptcy proceedings. The most critical development is the Chapter 11 filing of BioXcel Therapeutics, which has entered a stalking horse asset sale to Teva Pharmaceuticals for $57.5 million upfront, signaling a distressed exit for a biotech firm. A dominant theme is the cascade of Nasdaq minimum bid price and stockholders' equity failures, with 10 out of 14 companies receiving deficiency or delisting notices, many of which have already exhausted reverse stock split options (e.g., KALA BIO, GeoVax Labs). Period-over-period comparisons are limited due to the nature of the filings (8-Ks), but the data shows a clear pattern of deteriorating equity positions—My Size, Inc. reported equity of $2.347 million (below the $2.5 million threshold), and Oragenics Inc. reported $3.7 million (below $4 million). Insider trading activity is absent across all filings, which is a notable bearish signal as it suggests a lack of management confidence or an inability to trade due to blackout periods. Forward-looking statements are dominated by compliance plan deadlines and appeal processes, with no positive guidance revisions. The market implications are stark: a potential delisting wave could reduce liquidity and access to capital for these firms, while the BioXcel and Sangamo Therapeutics bankruptcies highlight the ongoing distress in the biotech sector. Portfolio-level patterns indicate that biotech and small-cap tech firms are the most vulnerable, with 6 out of 14 filings from biotech companies.

14 high priority 14 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 28, 2026

The USA Bankruptcy & Insolvency stream for August 28, 2026, reveals a concentrated wave of biopharma Chapter 11 filings, with both BioXcel Therapeutics and Sangamo Therapeutics entering court-supervised restructuring to monetize core assets via stalking horse auctions. BioXcel's deal with Teva Pharmaceuticals for $57.5M upfront plus up to $87.5M in milestones provides a floor valuation, while Sangamo's sale of its Fabry gene therapy asset (ST-920) to PTC Therapeutics lacks disclosed upfront consideration, signaling potentially distressed pricing. Both filings underscore a sector theme of cash-constrained biotechs liquidating pipeline assets to repay creditors, with no revenue growth or insider buying to offset negative sentiment. The absence of period-over-period comparisons or forward guidance in these initial filings limits trend analysis, but the materiality scores (10/10 and 9/10) highlight high-impact events for investors monitoring bankruptcy recoveries and distressed asset valuations.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 27, 2026

The four filings in this digest paint a stark picture of distress across micro-cap and pre-revenue life sciences companies, with three of the four facing imminent Nasdaq delisting threats. The dominant theme is a cascade of compliance failures, including late filings (Lottery.com), sub-$1.00 bid prices (Rein Therapeutics, Onfolio Holdings), and insufficient stockholders' equity (SOBR Safe). Period-over-period data from the enriched filings reveals a sector-wide pattern of deteriorating financial health, with no company reporting revenue growth or margin expansion. Insider activity is notably absent in all filings, suggesting a lack of management conviction to deploy personal capital. The most critical development is SOBR Safe's multi-faceted delisting risk, compounded by a director resignation and a cumulative reverse stock split ratio of 1-for-1100, making it the highest-risk name. Onfolio Holdings is the sole positive outlier, having regained compliance through a reverse split, but this is a temporary fix rather than a fundamental turnaround. The portfolio-level pattern is a 'distress cascade' where companies cycle through bid price, equity, and filing deficiencies, often exhausting all remedies.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 25, 2026

Today's filings paint a stark picture of distress across micro-cap and pre-commercial biotech companies, with 6 out of 7 issuers receiving Nasdaq deficiency notices for bid price, market value, or late filing violations. The cluster of three late filers (BioRestorative, Maison Solutions, and La Rosa Holdings) signals systemic accounting and liquidity problems. La Rosa Holdings stands out as the most acute case, with liabilities exceeding assets by $7.8M and cash burning at a 26% QoQ rate. All companies have been granted extended compliance periods (late Q4 2026 through early Q2 2027), creating a series of critical 'cure-or-delist' deadlines. No insider trading activity or capital allocation events were reported in any filing, suggesting management teams are largely sidelined. The primary themes are Nasdaq delisting risks, going-concern doubts, and liquidity crises.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 24, 2026

This intelligence stream covers four US-listed companies facing severe corporate distress, including three new delisting/receivership events and one ongoing filing delinquency. The filings reveal a cluster of micro-cap companies (Senmiao Technology, Northann Corp., Bubblr Inc.) facing terminal liquidity crises, with negative equity, trading suspensions, and court-ordered receivership. Hub Group, a larger logistics firm, represents a different distress pattern: repeated filing delinquencies without immediate trading impact, suggesting internal control failures rather than insolvency. The most critical development is Bubblr Inc.'s court-appointed receivership (Materiality 10/10), which effectively transfers corporate control to a court officer. Across all filings, period-over-period data is sparse, but the absence of positive financial trends is notable—Senmiao's negative equity of -$35.3 million and Northann's multi-section NYSE American violations indicate systemic governance failures. No insider trading activity, capital allocation actions, or forward guidance were disclosed in any filing, which is itself a bearish signal for transparency. The overarching theme is a wave of micro-cap delistings concentrated in the same week (August 18-21, 2026), likely triggered by accelerated regulatory enforcement and deteriorating balance sheets. Investors should expect heightened volatility in these names as OTC trading begins and legal proceedings unfold.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 24, 2026

The sole filing for the USA Bankruptcy & Insolvency stream on this quiet session is a highly material 8-K from Bubblr Inc. (BBLR), revealing that a U.S. District Court has appointed a Receiver for the company. This receivership represents a severe adverse regulatory action, effectively removing management's control and signaling acute financial distress. The filing provides no financial metrics, period-over-period comparisons, or forward-looking guidance, which is typical for such a sudden and extreme corporate event. The appointment of a Receiver is a precursor to potential liquidation or a forced restructuring, making this the single most critical development in the stream. The lack of any other filings underscores a very quiet session, with this event dominating the bankruptcy and insolvency landscape for the day.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 21, 2026

A massive wave of 16 8-K filings on a single day (August 21, 2026) reveals an acute corporate distress event across the US public markets, primarily concentrated in the healthcare and technology sectors. A staggering 15 of the 16 filings are from companies receiving Nasdaq deficiency or delisting notices, with materiality ratings of 8/10 or 9/10 in nearly every case. The three primary distress triggers are: (1) failure to maintain the minimum $1.00 bid price (5 companies: VivoSim Labs, Citius, BioCardia, Pasithea, Estrella), (2) failure to meet the minimum $2.5 million stockholders' equity requirement (4 companies: Silexion, TruGolf, Dragonfly Energy, Adial), and (3) failure to timely file periodic reports (3 companies: Global Interactive, SolarMax, Synergy CHC). The most severe cases involve Silexion Therapeutics and Rain Enhancement Technologies, which have already received delisting notices with imminent hearing deadlines; their shareholders' equity of only $44,000 and failure to cure market value deficiencies, respectively, place them in the highest risk category. This concentration highlights systemic weakness in micro-cap and pre-revenue biotech/life sciences companies that have been unable to access follow-on capital in a challenging market environment. There is no benign explanation for this cluster; it is a fundamental capital structure crisis.

16 high priority 16 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 20, 2026

Three US-listed small-cap companies received critical exchange compliance notices within a week (August 14-20, 2026), revealing a concentrated wave of corporate distress. The most severe case is Nukkleus Inc. (T3 Defense/DFNS), which faces Nasdaq delisting after its stockholders' equity collapsed by $62.2 million quarter-over-quarter (from +$42.5M to -$19.7M) due to a massive fair-value warrant loss—marking the most dramatic financial deterioration among the filings. Ocean Power Technologies (OPTT) represents a rapidly resolved risk, having cured its NYSE American late-filing delinquency by filing its 10-K just one day after the cure period ended, demonstrating administrative diligence. BullFrog AI Holdings (BFRG) received a second 180-day extension to meet the $1.00 bid price rule after its stock failed to recover during the initial period, signaling persistent equity market access issues. Across the filings, zero insider buying activity was detected, while all three companies share negative or mixed sentiment, pointing to a collective loss of investor and management confidence in the micro-cap space.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 19, 2026

The August 19, 2026 corporate distress landscape is dominated by acute delisting risks at two micro-cap biotech firms, Skye Bioscience and OSR Holdings, both of which received Nasdaq Staff Determinations. Skye faces a fundamental solvency crisis with negative stockholders' equity (-$497K vs. a $2.5M minimum), while OSR faces an imminent trading suspension on August 26 due to a chronic bid price deficiency, despite a massive, anomalous trading spike (370M shares on Aug 17). In contrast, Mereo BioPharma has been granted a second 180-day extension to cure its bid price deficiency, providing a longer runway until February 2027. The fourth filing, Trio-Tech International, is a voluntary, non-distressed listing transfer from NYSE American to Nasdaq, representing a neutral, administrative event. The key portfolio-level pattern is a bifurcation between companies with fundamental equity insolvency (Skye) and those with purely market-price-driven compliance issues (OSR, Mereo), with the former presenting a materially higher risk of permanent delisting. Insider activity data was absent from all filings, limiting conviction signals, but the forward-looking data creates a clear catalyst calendar of hearings and deadlines.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 18, 2026

The August 18, 2026 filings reveal a concentrated wave of corporate distress signals across three US public companies, all involving delisting or cessation of trading. Firsthand Technology Value Fund (SVVC) is pursuing a complete wind-down and liquidation after withdrawing its BDC status, with all independent directors resigning, signaling a terminal event. CID Holdco (DAICW) faces a dual crisis: a second Nasdaq delisting notice for failing to meet market value requirements and a lender default demanding over $1 million with foreclosure threats, indicating severe financial distress. Offerpad Solutions (OPAD) presents a contrasting, voluntary transfer from NYSE to Nasdaq, which is a neutral, strategic move rather than a distress signal. Period-over-period data was not available in the filings, limiting trend analysis, but the insider resignations at SVVC and the loan default at CID Holdco are critical negative signals. The overarching theme is a bifurcation between forced exits (SVVC, CID Holdco) and strategic listing changes (OPAD), with the former two representing high-probability bankruptcy or liquidation scenarios.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 17, 2026

The digest focuses on two US public companies showing significant distress signals, with one filing new and one carried over. Nexalin Technology reveals a critical, high-materiality (9/10) delisting risk from a Nasdaq stockholders' equity deficiency ($1.5M vs. $2.5M requirement) compounded by an existing bid price appeal, posing an immediate threat to liquidity and market access. Conversely, Cloudastructure, with a mixed sentiment filing (7/10), shows a classic growth-at-a-loss profile: subscription revenue surged 164% YoY and now dominates the mix (62%), but total revenue grew only 13% as hardware sales collapsed, and operating losses widened to $2.7M. While Nexalin presents a clear liquidation or restructuring risk, Cloudastructure's path to profitability is uncertain given rising expenses and cash burn. No positive sector themes emerge; both cases highlight heightened capital market scrutiny on small-cap, cash-burning entities. The aggregate period-over-period trend is one of deteriorating financial health and elevated delisting risk.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 14, 2026

On August 14, 2026, seven US public companies filed delisting notices, creating a dramatic cluster of corporate distress signals within a single 24-hour period. All filings are under Item 3.01 (failure to satisfy a continued listing rule or standard), with four (Adagio Medical, REED'S, Optimum Communications, Teads Holding) lacking any specific reason for delisting and no financial or forward-looking guidance, amplifying investor uncertainty. SES AI Corp's partial delisting of only its public warrants (SES WS) due to 'abnormally low selling price' stands out as a nuanced event, while Worksport Ltd and Actinium Pharmaceuticals carry critical-to-high risk designations. The compressed timing and lack of quantified financial impact across all filings suggest a sector-agnostic liquidity or compliance crisis, with the average materiality score of 8.6/10 underscoring portfolio-level risk. No positive period-over-period trends, insider activity, or capital allocation data were available, reinforcing a uniformly bearish and opaque distress environment.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 12, 2026

Both filings on August 12, 2026, reveal acute distress in micro-cap companies listed on Nasdaq, with CID Holdco (Dot Ai) and Generation Income Properties facing imminent delisting due to market value and bid price deficiencies. The common theme is a failure to maintain minimum listing standards despite prior compliance efforts, signaling severe liquidity and market confidence issues. CID Holdco's stock has collapsed in value, failing to meet the $50M MVLS threshold, while Generation Income Properties cannot sustain a $1.00 bid price and now faces a compounding equity deficiency. Neither company has shown any period-over-period revenue growth or margin improvement in the enriched data, and both lack insider buying or positive forward guidance, reinforcing a bearish outlook. The market implications are binary: delisting would likely trigger further price declines and loss of institutional access. These cases highlight a broader trend of struggling micro-caps unable to reverse valuation erosion in a selective market environment.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 11, 2026

The two filings in this stream both signal acute corporate distress, with one company facing imminent delisting and the other executing a radical pivot after abandoning its core business. Grove Collaborative Holdings received a NYSE non-compliance notice for failing to meet the $50 million minimum market capitalization and stockholders' equity thresholds, a classic precursor to delisting if a remediation plan is not accepted within 45 days. Hoth Therapeutics (now Rocket One Inc.) is simultaneously celebrating a strategic pivot into AI and space computing while disclosing a Nasdaq delisting notice and the fact that its licensed technologies remain pre-commercial, requiring substantial additional capital. The common theme is a severe erosion of market confidence and financial viability, with both companies trading at risk of losing their exchange listings. No period-over-period financial comparisons, insider trading activity, or capital allocation data were available in the enriched filings, limiting quantitative trend analysis but reinforcing the qualitative distress signals. The market implication is clear: both securities carry extreme downside risk from delisting, and any recovery thesis depends on improbable regulatory or operational turnarounds.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 10, 2026

This digest covers five US SEC filings, all flagged for corporate distress signals. The dominant theme is Nasdaq non-compliance and delisting risk, with three companies (Arcadia Biosciences, Lexaria Bioscience, and Northann Corp.) receiving explicit notices. A fourth, Construction Partners, faces a governance-related compliance issue. The fifth, Faraday Future, has resolved its bid price deficiency but remains in a precarious financial state. Period-over-period comparisons were largely absent from these filings, limiting trend analysis; however, the filings reveal a severe lack of liquidity and governance failures. The most critical development is the absence of remediation plans from Lexaria and Northann, suggesting a high probability of actual delisting. The market implications are significant: investors face potential total losses in companies unable to cure deficiencies, while others may see dilution from reverse stock splits. A portfolio-level pattern is the concentration of distress in micro-cap and pre-revenue companies, where cash burn and governance lapses are acute.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 07, 2026

This digest of 9 US SEC filings from August 7, 2026, reveals a surge in corporate distress signals across micro-cap stocks listed on the Nasdaq. A dominant theme is the widespread failure to maintain minimum bid prices and market value of listed securities (MVLS), with six out of nine filings (GIFTIFY, Avalanche, Neonode, Eightco, Barfresh, and Triller) directly addressing these deficiencies. This suggests a systemic liquidity and valuation crisis among companies with market caps likely below $50 million. More severe distress is evident in HeartSciences, which reported a critically low stockholders' equity of just $226,060 against a $2.5 million requirement and is tying its survival to an all-stock merger. The highest-risk event is NusaTrip's imminent delisting without appeal, linked to an SEC trading suspension and its majority owner's Chapter 11 bankruptcy. Period-over-period comparisons, while often unavailable due to 8-K filings, show deteriorating cash positions and mounting losses from annual reports, and a 'mixed' sentiment in Triller's filing underscores that compliance can be fragile. The aggregate intelligence points to a sector-wide shakeout where micro-cap companies are running out of financing options, with insider selling or silence and pending reverse split proposals adding further pressure. The key catalyst calendar is packed with compliance deadlines in early 2027, making these names high-risk, high-surveillance plays for distressed investors.

9 high priority 9 total filings